DSIP vs Octreotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →Side-by-Side Comparison
| Aspect | DSIP | Octreotide |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 50 mcg–600 mcg |
| Frequency | 1x daily | 3x daily |
| Cycle Length | 1–6 weeks | 4–24 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. |
| Typical Dosage | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. |
| Administration | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. |
| Side Effects | May cause grogginess upon waking, vivid dreams, or temporary headaches. | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. |
| Best For |
Key Differences
Unique to DSIP:
Unique to Octreotide:
Key Studies
DSIP
- Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
Frontiers in pharmacology, 2024
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
Journal of neurochemistry, 2006
- [DSIP: the sleep peptide or an unknown hypothalamic hormone?].
Zhurnal evoliutsionnoi biokhimii i fiziologii, 1994
Octreotide
- Octreotide Scan.
2025
- Octreotide and direct/indirect lung injury.
Research in pharmaceutical sciences, 2025
- Octreotide and Octreotide-derived delivery systems.
Journal of drug targeting, 2023
Ready to Learn More?
Looking for trusted sources?